GSK pays $950m for a pulmonary hypertension drug designed to avoid the bleeding risk that limits rival treatments

GSK has agreed to acquire Canadian biotech 35Pharma for $950 million in cash to secure HS235, an activin signalling inhibitor that completed phase I and is poised to enter trials in pulmonary arterial hypertension and pulmonary hypertension due to HFpEF. HS235 is engineered for enhanced selectivity to avoid BMP9/10 binding associated with bleeding risk in anticoagulated PH patients and shows early metabolic benefits that could broaden its clinical addressable market; activin inhibitors are forecast to capture roughly half of PH therapy revenues as the market grows toward an $18 billion opportunity by 2032. The deal complements GSK's respiratory, immunology and inflammation portfolio, targets an estimated US addressable population of ~100,000 patients, and remains subject to US and Canadian regulatory clearance.

Analysis

Market structure: GSK (GSK) is the clear near-term winner — the $950m deal buys a phase‑II ready platform into a PH market forecast ~$18bn by 2032 and a US addressable pool ~100k patients. Competing activin developers and pure‑play PH names (highly levered small caps) face pricing and market‑share pressure if HS235 proves safer for anticoagulated patients; incumbents in prostacyclin/endothelin classes (e.g., United Therapeutics, UTHR) could see slower growth or need to bundle/combine, pressuring gross‑to‑net dynamics over 3–7 years.

Risk assessment: Tail risks include regulatory rejection or post‑approval bleeding signal that wipes out premium (low probability, high impact), and rival Phase II/III wins that eclipse HS235’s selectivity; timeline: immediate (days) reaction to the deal, short‑term (3–12 months) readouts/INDs, long‑term (2–6 years) commercial adoption. Hidden dependencies: reimbursement for a high‑price biologic, label limitations with anticoagulant co‑therapy, patent life and manufacturing scale; catalysts are Phase‑2 starts (next 6–12 months), competitor data releases and payer modelling updates.

Trade implications: Primary trade is long GSK sized as a modest core pharma bet given diversification and optionality; hedge regulatory binary risk with long‑dated call spreads or modest short of pure‑play PH names. Cross‑asset: negligible sovereign/bond impact, GBP/USD may move transiently on deal framing; expect elevated equity options IV around clinical catalysts for small biotech peers.

Contrarian angles: Consensus may over‑inflate safety differentiation and metabolic upsell — metabolic signals from Phase I are noisy and could attract off‑label use scrutiny that slows launch; the $950m price tags a lot of binary development risk into GSK’s capex. If HS235 fails, GSK downside is capped (acquisition writedown) while small biotech shorts would rally; consider asymmetric plays exploiting this skew over 12–36 months.

Key Decisions for Investors

• Establish a 1.5–2.0% long position in GSK (GSK) within 1 week; target 12‑month return 15–25% if Phase‑2 initiation occurs and sentiment remains positive; set a hard stop at −8% and reassess on any regulatory denial or major bleeding signal.
• Implement a relative‑value pair: long GSK 2.0% vs short United Therapeutics (UTHR) 1.5% as a 12–36 month trade to capture platform optionality vs pure‑play PH exposure; tighten if HS235 posts neutral safety signals or competitor Phase‑2 success.
• Buy a 9–12 month GSK call spread (buy ATM, sell ~+30% OTM) sized to 0.5–1.0% of portfolio to leverage positive clinical/regulatory catalysts while capping premium; consider selling short‑dated calls to finance if IV spikes >30% from current levels.
• Trim 30–50% of small‑cap PH/activin‑focused biotech longs (early‑stage names) over the next 30 days and redeploy into large‑cap pharma (GSK) or cash; revisit holdings only after Phase‑2 readouts or clear payer modelling (monitor filings/events in next 60–120 days).